Publication: Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group UK
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sade-Feldman, M., Y. J. Jiao, J. H. Chen, M. S. Rooney, M. Barzily-Rokni, J. Eliane, S. L. Bjorgaard, et al. 2017. “Resistance to checkpoint blockade therapy through inactivation of antigen presentation.” Nature Communications 8 (1): 1136. doi:10.1038/s41467-017-01062-w. http://dx.doi.org/10.1038/s41467-017-01062-w.
Research Data
Abstract
Treatment with immune checkpoint blockade (CPB) therapies often leads to prolonged responses in patients with metastatic melanoma, but the common mechanisms of primary and acquired resistance to these agents remain incompletely characterized and have yet to be validated in large cohorts. By analyzing longitudinal tumor biopsies from 17 metastatic melanoma patients treated with CPB therapies, we observed point mutations, deletions or loss of heterozygosity (LOH) in beta-2-microglobulin (B2M), an essential component of MHC class I antigen presentation, in 29.4% of patients with progressing disease. In two independent cohorts of melanoma patients treated with anti-CTLA4 and anti-PD1, respectively, we find that B2M LOH is enriched threefold in non-responders (~30%) compared to responders (~10%) and associated with poorer overall survival. Loss of both copies of B2M is found only in non-responders. B2M loss is likely a common mechanism of resistance to therapies targeting CTLA4 or PD1.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service